CTIX has avoided toxic financing, which is what so

CTIX has avoided toxic financing, which is what so often kills small biotechs. That's what did in PolyMedix, it's why AMBS is now at a nickel, and there are untold numbers of other examples.

Here's one. CRMD has a seemingly very promising product which helps reduce infections in people who have an IV port permanently implanted. (common in diabetics and for other diseases, surgeries, etc.)

All those whiners on lieHUB who claim that the Aspire deal is bad (it's not) should look at this:

Quote:

---

Shares of CorMedix (CRMD) touched a new low since June 2013 on Friday morning after the biopharmaceutical firm said underwriter H.C. Wainwright & Co. agreed to increase the size of a public offering to $12 million from $10 million.
CRMD was down 37% with a new 52-week range of $0.64 to $4.50.
The underwriter agreed to acquire about 16.2 million CRMD common shares together with tranche 1 and tranche 2 warrants to purchase a total of 24.3 million shares at a price of $0.75 per share, which is a 27.9% discount relative to the stock's Thursday closing price.
CorMedix said it expects aggregate gross proceeds of $12.1 million and plans to use the net proceeds for general corporate purposes. The company also granted H.C. Wainwright a 30-day option to acquire up to 2.4 million additional shares and/or warrants to purchase 3.6 million shares, for potentially additional gross proceeds of up to about $1.8 million.

---